Evidence map›Paper›PMID 30309211›Full record

ArticleRadiation oncology journal2018

Effectiveness and feasibility of concurrent chemoradiotherapy using simultaneous integrated boost-intensity modulated radiotherapy with and without induction chemotherapy for locally advanced pancreatic cancer.

Eun Sang Oh, Tae Hyun Kim, Sang Myung Woo, Woo Jin Lee, Ju Hee Lee, Sang Hee Youn, Sung Sik Han, Sang Jae Park, Dae Yong Kim

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Radiation oncology journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Eun Sang OhProton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Tae Hyun KimProton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Sang Myung WooCenter for Liver Cancer, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Woo Jin LeeCenter for Liver Cancer, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Ju Hee LeeCenter for Liver Cancer, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Sang Hee YounProton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Sung Sik HanCenter for Liver Cancer, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Sang Jae ParkCenter for Liver Cancer, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.
Dae Yong KimProton Therapy Center, National Cancer Center Research Institute and Hospital, National Cancer Institute, Goyang, Korea.

Funding

National Cancer Center NCC1710030
6 · The paper itself

Abstract

purposeTo evaluate the effectiveness and feasibility of chemoradiotherapy (CRT) using simultaneous integrated boost-intensity modulated radiotherapy (SIB-IMRT) in locally advanced pancreatic cancer (LAPC) patients. MATERIALS AND

methodsBetween January 2011 and May 2015, 47 LAPC patients received CRT using SIB-IMRT. Prior to SIBIMRT, 37 patients (78.7%) received induction chemotherapy (IC-CRT group) and remaining 10 patients (21.3%) did not received induction chemotherapy (CRT group). During SIB-IMRT, all patients received concomitant chemotherapy, with gemcitabine (n = 37) and capecitabine (n = 10).

resultsAt the time of analysis, 45 patients had died and 2 patients remained alive and the median follow-up time was 14.2 months (range, 3.3 to 51.4 months). For all patients, the median times of local progression-free survival (LPFS), progression-free survival (PFS), and overall survival (OS) were 18.1, 10.3, and 14.2 months, respectively. The median time of LPFS between IC-CRT and CRT groups was similar (18.1 months vs. 18.3 months, p = 0.711). IC-CRT group had a higher trend in PFS (10.9 months vs. 4.1 months, p = 0.054) and had significantly higher OS (15.4 months vs. 9.5 months, p = 0.007) than CRT group. In multivariate analysis, the use of induction chemotherapy and tumor response were significant factors associated with OS (p < 0.05, each). During SIBIMRT, toxicity of grade ≥3 was observed in 7 patients (14.9%) in all patients.

conclusionCRT using SIB-IMRT is feasible and promising in LAPC patients.

Indexed as

Intensity-modulated radiotherapyPancreas neoplasmsRadiotherapySurvival

Identifiers

PMID30309211
PMCPMC6226140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.